You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
American Association for Clinical Chemistry
Improving healthcare through laboratory medicine
Home
|
Customer Service
|
Site Map
|
Cart
|
Login
About AACC
Members
Events
Government & Public Affairs
Resource Centers
Professional Development
Publications
AACC Store
>
Members
>
NACB - The AACC Academy
>
NACB Blog
Recent Posts
Newborn Screening for Severe Combined Immunodeficiency (SCID): Should it be performed?
Are reference change values more useful than population-based reference intervals?
Autoimmune diabetes and related conditions
Where Is the Hemoglobin S?
Categories
Cancer and Tumor Markers
Case Study
Clinical Translational Science/Proteomics
CVD/Markers/Risk Factors
Diabetes/Endocrinology
Government Affairs/Patient Safety
Immunology/Infectious Disease
Instrumentation/Technology
Management/Medical Informatics
Molecular Pathology and Genetics
New/Other Disease Markers
Nutrition
POC Testing
Renal/GI/Hepatic
Special Populations
TDM/Toxicology
Archives
Year
: 2013
May 2013
April 2013
March 2013
February 2013
January 2013
Year
: 2012
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
Year
: 2011
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
RSS Feed
NACB Blog
Laboratory Developed Tests: How Will FDA Regulation Affect Us?
10/25/2011 8:15 AM |
Comments (1)
Recommend (790)
By
Patricia M. Jones, PhD, DABCC, FACB
Laboratory developed tests (LDTs) used to be referred to as home-brew tests or in-house tests. These are assays that are developed in one’s own laboratory, and they include a wide range of tests. LDTs can be as simple as colorimetric tests like the old Apt-Downey test for fetal hemoglobin, all the ...(
Read More
)
Posted at 10/25/2011 8:15 AM | Tags:
Government Affairs/Patient Safety
Evaluation of Multiple Myeloma
10/18/2011 8:19 AM |
Comments (1)
Recommend (827)
By
Joshua Bornhorst, PhD
Multiple myeloma is a malignant neoplasm, usually involving a single clone of plasma cells, which produce immunoglobulins of uniform structure (Most commonly IgG, but all other immunoglobulin chains are also represented). This disorder usually strikes individuals 60 years of age or older, but can ...(
Read More
)
Posted at 10/18/2011 8:19 AM | Tags:
Cancer and Tumor Markers
Direct-to-Consumer Genomics: Opening Pandora’s Box?
10/11/2011 8:05 AM |
Comments (3)
Recommend (845)
By
K.T. Jerry Yeo, PhD
The general public is increasingly interested in the promise of personal genomics for reasons ranging from health concerns to recreation. This is due to a convergence of web-based social networking and high throughput sequencing, leading to an “explosion” of DTC genomic companies in the past 5 yea...(
Read More
)
Posted at 10/11/2011 8:05 AM | Tags:
Molecular Pathology and Genetics
Was Illness or Treatment Responsible for this Impairment?
10/4/2011 8:48 AM |
Comments (2)
Recommend (857)
By
Donald L. Frederick, PhD, DABFT
In a case reported by the Scientific Analysis Bureau of the Arizona Department of Public Safety, a 44-year-old male was stopped by Tucson police for extremely erratic driving. The subject drifted out of his lane repeatedly, nearly hitting an overpass wall. He did not respond to police lights, so th...(
Read More
)
Posted at 10/4/2011 8:48 AM | Tags:
TDM/Toxicology
(Hidden) Admin Links
About AACC
|
Members
|
Government & Public Affairs
|
Resource Centers
|
Professional Development
|
Publications
Home
|
Customer Service
|
Site Map
|
AACC Store
|
Login
Contact Us
|
Privacy Policy and Legal Disclaimer
|
Join AACC
©2013 American Association for Clinical Chemistry
1850 K Street, NW Suite 625
Washington, DC 20006
Phone: (800) 892-1400 | Fax: (202) 887-5093